Lung Cancer News and Research

Latest Lung Cancer News and Research

Light may just be the answer for solving sleep problems among lung cancer patients

When you're having trouble sleeping, light is the last thing you assume you need. But according to a pilot study attempting to solve insomnia among lung cancer patients led by University at Buffalo sleep researcher Grace Dean, light may just be the answer.

26 Jun 2015

Breast cancer treatment market estimated to increase to over $13.1 billion by 2020

Analysis from business intelligence provider GBI Research - Breast Cancer Therapeutics in Major Developed Markets to 2020 - forecasts the breast cancer treatment market to increase in value from $9.2 billion in 2013 to more than $13.1 billion by 2020, representing a Compound Annual Growth Rate (CAGR) of 5.1%.

24 Jun 2015

Annual LDCT screening safe, effective for monitoring patients with nonsolid lung nodules

An annual exam using a key imaging technology could spare patients with lung nodules from unnecessary tests and surgery, while identifying the cases where the nodules are likely to become cancerous, according to a new study by researchers at Icahn School of Medicine at Mount Sinai (ISMMS) and published online today in journal Radiology.

24 Jun 2015

VolitionRx teams up with market access consulting agencies to support access of NuQ cancer tests across Europe

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has established partnerships with two prominent market access consulting agencies, DecideumCogentia and MedPass International, to support market access of its NuQ® cancer tests across Europe.

24 Jun 2015

Understanding of tumor biology opens new opportunities to conduct clinical trial for thoracic tumors

Our understanding of tumor biology has improved and continues to expand at a rapid pace, and this has opened new opportunities for cancer clinical trials, particularly for thoracic tumors. The identification and molecular alterations in the cancer and the possibility to specifically and selectively target them, has dramatically improved the treatment efficacy in patients with lung cancer.

24 Jun 2015

Selective use of biomarker testing for breast cancer patients can save millions of dollars in health care spending

A review of medical records for almost 200 patients with breast cancer suggests that more selective use of biomarker testing for such patients has the potential to save millions of dollars in health care spending without compromising care, according to Johns Hopkins researchers.

23 Jun 2015

Low-dose CT screening can help monitor people who have nonsolid lung nodules

People who have nonsolid lung nodules can be safely monitored with annual low-dose computed tomography (CT) screening, according to a new study published online in the journal Radiology. Researchers said the findings could help spare patients from unnecessary surgery and additional imaging.

23 Jun 2015

Long-term smokers and ex-smokers have respiratory-related impairments

More than half of long-term smokers and ex-smokers who are considered disease-free because they passed lung-function tests have respiratory-related impairments when more closely evaluated with lung imaging, walking and quality-of-life tests. Many of those people likely have the earliest stages of chronic obstructive pulmonary disease, an incurable progressive disease (COPD) that is the third leading cause of death in the United States.

23 Jun 2015

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

Benitec Biopharma is pleased to announce the launch of a new exploratory cellular therapy program including exosome-based delivery utilising the Company's proprietary ddRNAi technology. Entry into these areas have been facilitated by the commencement of a collaboration with UK-based stem cell therapeutics company, ReNeuron.

22 Jun 2015

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant.

19 Jun 2015

Simple test could help identify genetically inherited risk for prostate cancer

Men with an elevated, genetically inherited risk for prostate cancer could be routinely identified with a simple blood or urine test, scientists at UC San Francisco and Kaiser Permanente Northern California have concluded, potentially paving the way to better or earlier diagnosis.

18 Jun 2015

Loyola tests new combination treatment for people living with cancer that has spread to spine

Loyola University Medical Center is the first center in the country to enroll patients in a clinical trial of a minimally invasive treatment for patients living with cancer that has spread to the spine.

17 Jun 2015

Nanoplatform technology that detects early stages of cancer receives U.S. patent

A U.S. patent has been awarded to a Kansas State University technology that quickly detects the early stages of cancer before physical symptoms ever appear.

17 Jun 2015

Improving air quality could prevent pollution-related deaths worldwide

Improving air quality -- in clean and dirty places -- could reduce pollution-related deaths worldwide by millions of people each year. That finding comes from a team of environmental engineering and public health researchers who developed a global model of how changes in outdoor air pollution could lead to changes in the rates of health problems such as heart attack, stroke and lung cancer.

16 Jun 2015

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Ventana Medical Systems, Inc., a member of the Roche Group, today announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI (crizotinib).

15 Jun 2015

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries.

15 Jun 2015

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to evaluate scientifically targeted combination approaches with afatinib in the treatment of non-small cell lung cancer (NSCLC).

12 Jun 2015

Lung cancer patients with comorbid conditions face higher risk of death

Lung cancer patients with comorbid conditions such as chronic obstructive pulmonary disease, diabetes, or congestive heart failure had a higher risk of death than lung cancer patients without comorbid conditions, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

12 Jun 2015

PGDx launches LungSelect product to identify genetic alterations in the plasma of NSCLC patients

Personal Genome Diagnostics, Inc., a provider of advanced cancer genome analysis and testing services, today announced the launch of its LungSelect product that identifies the most common, clinically actionable genetic alterations in the plasma of non-small cell lung cancer (NSCLC) patients.

11 Jun 2015

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

This week, Lancet Oncology reports results of a 1,093-person phase III clinical trial of the drug necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.

11 Jun 2015

Lung Cancer News and Research

Latest Lung Cancer News and Research

Light may just be the answer for solving sleep problems among lung cancer patients

Breast cancer treatment market estimated to increase to over $13.1 billion by 2020

Annual LDCT screening safe, effective for monitoring patients with nonsolid lung nodules

VolitionRx teams up with market access consulting agencies to support access of NuQ cancer tests across Europe

Understanding of tumor biology opens new opportunities to conduct clinical trial for thoracic tumors

Selective use of biomarker testing for breast cancer patients can save millions of dollars in health care spending

Low-dose CT screening can help monitor people who have nonsolid lung nodules

Long-term smokers and ex-smokers have respiratory-related impairments

Benitec, ReNeuron collaborate to launch new exploratory cellular therapy program

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Simple test could help identify genetically inherited risk for prostate cancer

Loyola tests new combination treatment for people living with cancer that has spread to spine

Nanoplatform technology that detects early stages of cancer receives U.S. patent

Improving air quality could prevent pollution-related deaths worldwide

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug

NCCN ORP receives $2-million grant from Boehringer Ingelheim to facilitate studies of afatinib in NSCLC

Lung cancer patients with comorbid conditions face higher risk of death

PGDx launches LungSelect product to identify genetic alterations in the plasma of NSCLC patients

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in